TrialAdvances in therapy2024

Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.

Ying Cheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.